Dynamic-shared Pharmacophore Approach as Tool to Design New Allosteric PRC2 Inhibitors, Targeting EED Binding Pocket

Mol Inform. 2021 Feb;40(2):e2000148. doi: 10.1002/minf.202000148. Epub 2020 Sep 16.

Abstract

The Polycomb Repressive complex 2 (PRC2) maintains a repressive chromatin state and silences many genes, acting as methylase on histone tails. This enzyme was found overexpressed in many types of cancer. In this work, we have set up a Computer-Aided Drug Design approach based on the allosteric modulation of PRC2. In order to minimize the possible bias derived from using a single set of coordinates within the protein-ligand complex, a dynamic workflow was developed. In details, molecular dynamic was used as tool to identify the most significant ligand-protein interactions from several crystallized protein structures. The identified features were used for the creation of dynamic pharmacophore models and docking grid constraints for the design of new PRC2 allosteric modulators. Our protocol was retrospectively validated using a dataset of active and inactive compounds, and the results were compared to the classic approaches, through ROC curves and enrichment factor. Our approach suggested some important interaction features to be adopted for virtual screening performance improvement.

Keywords: Drug design; Dynamic pharmacophore; EED; Molecular Dynamic; PRC2.

MeSH terms

  • Allosteric Site*
  • Binding Sites*
  • Drug Design*
  • Humans
  • Ligands
  • Molecular Docking Simulation*
  • Molecular Dynamics Simulation*
  • Polycomb Repressive Complex 2 / antagonists & inhibitors*
  • Polycomb Repressive Complex 2 / chemistry*
  • Protein Binding
  • ROC Curve

Substances

  • Ligands
  • Polycomb Repressive Complex 2